Salix Coronary Plaque vs VX1+

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Artrya
VS
by Volta Medical

AI Verdict

Tool A, Salix Coronary Plaque, focuses on the diagnostic assessment of coronary artery disease by analyzing CCTA scans for plaque and stenosis. In contrast, Tool B, VX1+, is an intra-procedural tool designed to assist electrophysiologists in real-time during cardiac ablation procedures for atrial fibrillation and tachycardia. While both are AI-powered cardiology tools, their distinct applications—diagnostic imaging analysis versus real-time interventional guidance—make them suitable for different stages of patient care and specific cardiology sub-specialties.

Choose Salix Coronary Plaque if…

Choose Salix Coronary Plaque if your primary goal is to rapidly and accurately diagnose coronary artery disease and assess patient risk using CCTA scans. This tool is ideal for cardiologists and radiologists needing detailed, AI-driven quantification of coronary plaque, including high-risk features and stenosis, for informed treatment planning and patient management.

View Salix Coronary Plaque →

Choose VX1+ if…

Choose VX1+ if you are an electrophysiologist seeking real-time, AI-powered guidance during cardiac ablation procedures for atrial fibrillation or tachycardia. This software is designed to assist in identifying abnormal electrograms and optimizing ablation targets, aiming to improve procedural efficacy by providing critical insights directly within your existing EP recording and 3D mapping systems.

View VX1+ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Salix Coronary Plaque VX1+
Pricing Subscription model Unknown
Deployment Cloud-based (Amazon Web Services), web-based software application Software, compatible with most multipolar catheters and mapping technologies used in operating rooms or electrophysiology labs.
BAA Available Yes AI-estimated Unknown
FDA Status Yes AI-estimated Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both tools are designed for seamless integration and ease of use within their respective clinical environments. Tool A offers a web-based platform with 3D visualization and integrated workflow management for rapid assessment, while Tool B features a simple, color-coded user interface and compatibility with existing EP systems, with upcoming automated tagging capabilities. Both prioritize efficient workflow and user experience.

Clinical Value

VX1+

While both are FDA-cleared and address critical cardiac conditions, Tool B (VX1+) has demonstrated superior efficacy in randomized controlled trials (TAILORED-AF) compared to standard care for persistent AF, showing improved patient outcomes and standardization of complex procedures. Tool A provides significant diagnostic value by identifying high-risk plaque features, with ongoing studies to further validate its prognostic value, but direct comparative outcome superiority against standard care is not as explicitly established in the provided information.

Pricing & Value

Salix Coronary Plaque

Tool A offers clear pricing transparency with a per-scan assessment model and a defined US CPT reimbursement rate of US$950, providing a tangible financial incentive for healthcare providers. In contrast, Tool B's pricing is not publicly available, making its direct financial value proposition less transparent, despite claims of potential cost reductions through improved outcomes.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness, being FDA-cleared and designed for integration into existing clinical workflows. Tool A's cloud deployment offers scalability and ease of access, while Tool B's compatibility with a wide range of existing EP recording and 3D mapping systems is a significant advantage for adoption. Both are expected to adhere to necessary HIPAA and BAA compliance standards.

Innovation

VX1+

Tool B stands out as the first FDA-cleared AI-based tool in interventional cardiac electrophysiology, providing real-time guidance during live ablation procedures to address a critical challenge in AF treatment. Its proven ability to standardize outcomes and improve efficacy in complex procedures, coupled with industry recognition like the Prix Galien Award, indicates a higher degree of groundbreaking innovation. Tool A's advanced plaque characterization from CCTA is also innovative, but Tool B's real-time interventional guidance is a more novel application of AI in this context.

Support & Docs

Tie

Both tools explicitly mention the availability of a user manual (Artrya Salix User Guide for Tool A and VX1TM SYSTEM USER MANUAL for Tool B). However, neither provides further specific details regarding dedicated customer support channels, training programs, or the comprehensiveness of their documentation beyond these basic mentions. Therefore, it is difficult to distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Salix Coronary Plaque VX1+
Description FDA-cleared, AI-driven, web-based software that provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease. AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.
Company Artrya Limited Volta Medical
Categories Cardiology AI Cardiology AI, Surgical AI
Specialties Cardiology, Radiology Cardiology
Key Features AI-enabled CCTA analysis, Near real-time, point-of-care assessment, Detection and quantification of coronary plaque (atherosclerosis), Identification of high-risk plaque features (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign), Stenosis assessment, Quantification of calcifications (calcium scoring), Integrated workflow management, Automated report generation (editable). Real-time manual or automatic annotation of 3D anatomical and electrical maps of the human heart, Identification of spatio-temporal dispersed electrograms (DEs) during AF and AT procedures, AI-driven insights to assist electrophysiologists during ablation procedures, Compatibility with existing 510(k)-cleared catheters and specific data acquisition systems (e.g., Boston Scientific LabSystem Pro, GE HealthCare MacLab CardioLab EP Recording System, Abbott EnSite X 3D mapping system), Non-sterile reusable medical device, Simple user interface with color coding for electrogram dispersion (blue, orange, red), Booster mode for increased sensitivity during AT or slow AF, Provides cycle length estimation from electrograms.

Videos

Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and VX1+.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Salix Coronary Plaque (Tool A) is designed for the rapid and accurate diagnosis of coronary artery disease by providing near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans. VX1+ (Tool B) assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.
Salix Coronary Plaque (Tool A) is intended for cardiologists and radiologists who interpret CCTA scans for coronary artery disease. VX1+ (Tool B) is specifically designed to assist electrophysiologists during cardiac ablation procedures.
Salix Coronary Plaque (Tool A) analyzes CCTA scans to detect and quantify coronary plaque and stenosis. VX1+ (Tool B) analyzes electrogram data to identify spatio-temporal dispersed electrograms (DEs) during AF and AT procedures.
Salix Coronary Plaque (Tool A) operates on a per-scan assessment model and qualifies for a US CPT reimbursement rate of US$950 per assessment. Pricing for VX1+ (Tool B) is not publicly available.
Salix Coronary Plaque (Tool A) provides near real-time, point-of-care assessment of CCTA scans, with assessments available in less than 10 minutes. VX1+ (Tool B) offers real-time identification of abnormal electrograms during cardiac ablation procedures.
AI Tool Finder
AI-powered search. Results may not be comprehensive.